EP1103252B1 — Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method
Assigned to Laboratorios Liconsa SA · Expires 2003-03-12 · 23y expired
What this patent protects
Pharmaceutical preparation comprising a compound having an antifungic activity as active principle, an inert core and a coat which includes said active principle, and is characterized in that said inert core has a particle size between 50 and 600 mu m, and is also characterized …
USPTO Abstract
Pharmaceutical preparation comprising a compound having an antifungic activity as active principle, an inert core and a coat which includes said active principle, and is characterized in that said inert core has a particle size between 50 and 600 mu m, and is also characterized in that said coat has a unique layer which is produced by nebulization, on said inert core, of a solution which comprises a compound having an antifungic activity, a hydrophilic polymer and a non ionic surfactant. The method is carried out by means of a coating which comprises a unique layer of the inert cores having a size comprised between 50 and 600 mu m by nebulization of a solution comprised of the antifungic agent, the hydrophilic polymer and the non ionic surfactant at constant coating speed throughout the process; a single drying process of the coat is required with the same equipment.
Drugs covered by this patent
- Aveed (TESTOSTERONE UNDECANOATE) · Marius
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.